Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?

The Pharmacogenomics Journal volume 9, pages 395–403 (2009)Cite this article

Abstract

The cytochrome P450 2D6 (CYP2D6) isoenzyme metabolizes about 25% of clinically used drugs. The impact of CYP2D6 metabolizer status on therapeutic outcome was assessed in 365 psychiatric in-patients treated with neuroleptics or antidepressants. Length of hospitalization and response onset were prolonged for patients receiving CYP2D6 drugs. Intermediate metabolizers (IMs) receiving CYP2D6 doses above the population median had more side effects after 4 weeks than extensive metabolizers with above-median doses (9/13, 69% vs 4/23, 17%, P=0.003), than IMs with below-median doses (5/22, 23%, P=0.012) and IMs with other medication (24/84, 29%, P=0.009). The Clinical Global Impression scale response was lower for IMs treated with CYP2D6 drugs (3/42, 7%) than for IMs with other medication (21/84, 25%, P=0.017) probably due to increased side effects. Identification of IM status (38% of study population) may help to reduce side effects and length/cost of hospitalization. Thus, not only poor and ultrarapid metabolizer but also IMs may benefit from CYP2D6 genotyping. This is of paramount interest since it greatly improves cost/benefit estimations for pretreatment CYP2D6 screening.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Ingelman-Sundberg M, Rodriguez-Antona C . Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci 2005; 360: 1563–1570.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Nebert DW . Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 1997; 60: 265–271.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Ingelman-Sundberg M . Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 89–104.

    Article  CAS  PubMed  Google Scholar 

  4. Bradford LD . CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3: 229–243.

    Article  CAS  PubMed  Google Scholar 

  5. Raimundo S, Toscano C, Klein K, Fischer J, Griese EU, Eichelbaum M et al. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther 2004; 76: 128–138.

    Article  CAS  PubMed  Google Scholar 

  6. Wuttke H, Rau T, Heide R, Bergmann K, Bohm M, Weil J et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002; 72: 429–437.

    Article  CAS  PubMed  Google Scholar 

  7. Chou WH, Yan FX, de Leon J, Barnhill J, Rogers T, Cronin M et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 2000; 20: 246–251.

    Article  CAS  PubMed  Google Scholar 

  8. Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants—a pilot study. Clin Pharmacol Ther 2004; 75: 386–393.

    Article  CAS  PubMed  Google Scholar 

  9. Brockmoller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72: 438–452.

    Article  PubMed  Google Scholar 

  10. Kawanishi C, Lundgren S, Agren H, Bertilsson L . Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 2004; 59: 803–807.

    Article  CAS  PubMed  Google Scholar 

  11. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173–192.

    Article  CAS  PubMed  Google Scholar 

  12. de Leon J . The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19. J Clin Psychopharmacol 2007; 27: 241–245.

    Article  PubMed  Google Scholar 

  13. Flockhart DA . Drug interactions: cytochrome P450 drug interaction table (version 4.0). Indiana University School of Medicine (2007) (cited 2009); Available from: http://medicine.iupui.edu/flockhart/table.htm.

  14. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J . Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics 2002; 12: 571–580.

    Article  CAS  PubMed  Google Scholar 

  15. World Health Organization. Anatomical Therapeutic Chemical (ATC) index 2008 including defined daily doses (DDD). Available from: http://www.whocc.no/atcddd/. Accessed 2008 [updated Accessed 2008; cited 2008].

  16. Spina E, Scordo MG, D'Arrigo C . Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 2003; 17: 517–538.

    Article  CAS  PubMed  Google Scholar 

  17. Sjoqvist F, Eliasson E . The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther 2007; 81: 899–902.

    Article  CAS  PubMed  Google Scholar 

  18. de Leon J, Barnhill J, Rogers T, Boyle J, Chou WH, Wedlund PJ . Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital. Am J Psychiatry 1998; 155: 1278–1280.

    Article  CAS  PubMed  Google Scholar 

  19. Schillevoort I, de Boer A, van der Weide J, Steijns LS, Roos RA, Jansen PA et al. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case–control study. Pharmacogenetics 2002; 12: 235–240.

    Article  CAS  PubMed  Google Scholar 

  20. Ellingrod VL, Schultz SK, Arndt S . Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6. Pharmacotherapy 2002; 22: 1416–1419.

    Article  PubMed  Google Scholar 

  21. Furman KD, Grimm DR, Mueller T, Holley-Shanks RR, Bertz RJ, Williams LA et al. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. Pharmacogenetics 2004; 14: 279–284.

    Article  CAS  PubMed  Google Scholar 

  22. Mihara K, Otani K, Tybring G, Dahl ML, Bertilsson L, Kaneko S . The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients. J Clin Psychopharmacol 1997; 17: 467–471.

    Article  CAS  PubMed  Google Scholar 

  23. Zanger UM, Fischer J, Raimundo S, Stuven T, Evert BO, Schwab M et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 2001; 11: 573–585.

    Article  CAS  PubMed  Google Scholar 

  24. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM . Elucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000; 10: 577–581.

    Article  CAS  PubMed  Google Scholar 

  25. Hamelin BA, Dorson PG, Pabis D, Still D, Bouchard RH, Pourcher E et al. CYP2D6 mutations and therapeutic outcome in schizophrenic patients. Pharmacotherapy 1999; 19: 1057–1063.

    Article  CAS  PubMed  Google Scholar 

  26. Steimer W, Zopf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 2005; 51: 376–385.

    Article  CAS  PubMed  Google Scholar 

  27. Guy W . ECDEU Assessment Manual for Psychopharmacology. DHEW publication no. 76-338 US National Institute of Mental Health: Bethesda (MD), 1976.

    Google Scholar 

  28. Muller B, Zopf K, Bachofer J, Steimer W . Optimized strategy for rapid cytochrome P450 2D6 genotyping by real-time long PCR. Clin Chem 2003; 49: 1624–1631.

    Article  PubMed  Google Scholar 

  29. Steimer W, Muller T, Popp J, Heres S, Kissling W, Leucht S . Rapid detection of the intermediate metabolizer associated CYP2D6 polymorphisms*9 and*17 with real time PCR. Ther Drug Monit 2005; 27: 242–243.

    Google Scholar 

  30. Ji L, Pan S, Marti-Jaun J, Hanseler E, Rentsch K, Hersberger M . Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin Chem 2002; 48: 983–988.

    CAS  PubMed  Google Scholar 

  31. Sachse C, Brockmoller J, Bauer S, Roots I . Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284–295.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Steimer W, Zopf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem 2004; 50: 1623–1633.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar, Technische Universität München, München, Germany

    B Laika & W Steimer

  2. Psychiatrische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, München, Germany

    S Leucht & S Heres

Authors
  1. B Laika
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Leucht
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Heres
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W Steimer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W Steimer.

Additional information

Duality of interest

None declared.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laika, B., Leucht, S., Heres, S. et al. Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?. Pharmacogenomics J 9, 395–403 (2009). https://doi.org/10.1038/tpj.2009.23

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2009.23

Keywords

This article is cited by

Search

Advanced search

Quick links